Found 1 Presentation For Request "54p"
54P - Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2)
- John Bridgewater (London, United Kingdom)
Abstract
Background
Methods
Pts enrolled had locally advanced/metastatic iCCA with
Results
Interim data for 67 pts (58% female; median age 57 y) with ≥6 mo of follow-up are reported. Pts had CR, complete response; PD, disease progression; PR, partial response; SD, stable disease. aTwo mutations in
Comutation Patients, n CR PR SD PD 0 0 3 0 2 1 0 2 1 0 2 1 1 0 3 2 3 3 0 0 1 2 3 0 PI3K 0 1 3 0 1 3
Conclusions
These interim data demonstrate manageable AEs and efficacy of futibatinib in iCCA with
Clinical trial identification
NCT02052778; EudraCT: 2013-004810-16.
Editorial acknowledgement
Professional medical writing and editorial assistance were provided by Ashfield Healthcare Communications (Lyndhurst, NJ, USA) and funded by Taiho Oncology, Inc.
Legal entity responsible for the study
Taiho Oncology, Inc.
Funding
Taiho Oncology, Inc.
Disclosure
J. Bridgewater: Advisory/Consultancy: Taiho. F. Meric-Bernstam: Advisory/Consultancy: PACT Pharma, Inflection Biosciences, Pieris Pharmaceuticals, Clearlight Diagnostics, DarwinHealth; Advisory/Consultancy: Samsung Bioepis, Spectrum Biotech, Aduro Biotech, OrigiMed; Advisory/Consultancy: Mersana, Silverback Therapeutics, Immunomedics, IBM Watson Health; Research grant/Funding (self): Guradant Health, Daiichi Sankyo, GlaxoSmithKline; Speaker Bureau/Expert testimony: Chugai Pharma; Travel/Accommodation/Expenses: Beth Israel Deaconess Medical Center; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Seattle Genetics; Honoraria (self): Sumitomo Group, Dialectica; Research grant/Funding (self): Novartis, AstraZeneca, Calithera Biosciences, Bayer, Aileron Therapeutics, PUMA Biotechnology, CytomX Therapeutics; Advisory/Consultancy, Research grant/Funding (self): Genentech, Debiopharm, eFFECTOR Therapeutics; Research grant/Funding (self), Travel/Accommodation/Expenses: Taiho Pharmaceutical; Research grant/Funding (self): Jounce Therapeutics, Zymeworks, Curis, Pfizer, Abbvie, Boehringer Ingelheim. A. Hollebecque: Honoraria (self), Research grant/Funding (self), Travel/Accommodation/Expenses: Incyte; Honoraria (self): Amgen; Travel/Accommodation/Expenses: Servier; Honoraria (self): Merck Serono; Travel/Accommodation/Expenses: Lilly; Honoraria (self): Eisai. J.W. Valle: Advisory/Consultancy: AstraZeneca, Merck, Delcath Systems, Agios; Advisory/Consultancy: PCI Biotech, Incyte, Keocyt, QED Therapeutics, Pieris Pharmaceuticals, Genoscience Pharma; Advisory/Consultancy: Mundipharma EDO GmbH, Wren Laboratories, Nucana, Servier, Debiopharm Group; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Nucana; Advisory/Consultancy, Speaker Bureau/Expert testimony: Imaging Equipment Limited; Travel/Accommodation/Expenses: Celgene; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Ipsen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): Novartis. C. Morizane: Advisory/Consultancy: Abbvie; Honoraria (self), Advisory/Consultancy: Novartis, Taiho Pharmaceutical,; Honoraria (self): Teijin Pharma, Merck Sharp & Dohme; Honoraria (self), Research grant/Funding (self): Eisai; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Yakult Honsha; Research grant/Funding (self): ONO Pharmaceutical, Taiho Pharmaceutical, J-Pharma, AstraZeneca, Merck. T. Karasic: Research grant/Funding (self): Syndax; Research grant/Funding (self): Taiho Pharmaceutical; Research grant/Funding (self): Celgene; Research grant/Funding (self): H3 Biomedicine; Research grant/Funding (self): Bristol-Myers Squibb; Research grant/Funding (self): Lilly; Research grant/Funding (self): Sirtex Medical. J. Furuse: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Taiho Pharmaceutical; Research grant/Funding (self): Ono Pharmaceutical, Merck Sharp & Dohme, Sumitomo Dainippon, J-Pharma, Yakult Honsha, AstraZeneca, Daiichi Sankyo, Eisai, Bayer, Pfizer, NanoCarrier, Kyowa Hakko Kirin, Taiho Pharmaceutical, Chugai Pharma, Sanofi, Takeda, Mochida Pharmaceutical, Astellas; Honoraria (self): Eisai, Bayer Yakuhin, Taiho Pharmaceutical, Ono Pharmaceutical, Novartis, Yakult Honsha, Teijin pharma, Shionogi, EA pharma, Eli Lilly Japan, Takeda, Chugai Pharma, Mochida Pharmaceutical, Nihon Servier, Sanofi, Fujifilm Toyama Chemical, Nobel pharma, Pfi. R.K. Kelley: Research grant/Funding (institution): Taiho, Novartis, QED, Partner Therapeutics, Exelixis, EMD Serono, Eli Lilly, Bayer, Adaptimmune; Advisory/Consultancy, Research grant/Funding (institution): Agios, AstraZeneca, BMS, Merck; Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Genentech/Roche; Advisory/Consultancy: Gilead. P. Cassier: Honoraria (institution): Taiho; Honoraria (self), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution): Abbvie; Honoraria (institution): Bayer; Honoraria (institution): BMS; Honoraria (self), Honoraria (institution): Blueprint; Honoraria (institution): GlaxoSmithKline; Honoraria (institution): Janssen; Honoraria (institution): Lilly; Honoraria (self), Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Honoraria (institution): Roche/Genentech. H-J. Klümpen: Research grant/Funding (institution): Bayer; Advisory/Consultancy: Ipsen. N. Uboha: Advisory/Consultancy, Research grant/Funding (self): Taiho Inc; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): Eli Lilly; Advisory/Consultancy: Incyte; Advisory/Consultancy, Research grant/Funding (self): EMD Serono; Advisory/Consultancy, Research grant/Funding (self): Ipsen. E. Mitchell: Advisory/Consultancy, Research grant/Funding (institution): Exilixis; Research grant/Funding (institution): Genentech; Advisory/Consultancy: BMS; Advisory/Consultancy: Merck; Advisory/Consultancy: Novartis. Y. He: Full/Part-time employment: Taiho Oncology. K. Benhadji: Shareholder/Stockholder/Stock options, Full/Part-time employment: Lilly; Full/Part-time employment: Taiho Oncology. L. Goyal: Advisory/Consultancy, Travel/Accommodation/Expenses: Debiopharm Group; Advisory/Consultancy: Alentis Therapeutics; Advisory/Consultancy: QED Therapeutics; Advisory/Consultancy: H3 Biomedicine; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Klus Pharma; Advisory/Consultancy: Agios; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Taiho Pharmaceutical. All other authors have declared no conflicts of interest.